+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine



Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine



Cochrane Database of Systematic Reviews 2013(10): Cd004389



Plasmodium vivax infections are an important contributor to the malaria burden worldwide. The World Health Organization recommends a 14-day course of primaquine (0.25 mg/kg/day, giving an adult dose of 15 mg/day) to eradicate the liver stage of the parasite and prevent relapse of the disease. Many people find a 14-day primaquine regimen difficult to complete, and there is a potential risk of haemolytic anaemia in people with glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency. This review evaluates primaquine in P. vivax, particularly alternatives to the standard 14-day course. To compare alternative primaquine regimens to the recommended 14-day regimen for preventing relapses (radical cure) in people with P. vivax malaria treated for blood stage infection with chloroquine. We also summarize trials comparing primaquine to no primaquine that led to the recommendation for the 14-day regimen. We searched the Cochrane Infectious Diseases Group's Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE and LILACS up to 8 October 2013. We checked conference proceedings, trial registries and reference lists and contacted researchers and pharmaceutical companies for eligible studies. Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine. We independently assessed trial eligibility, trial quality, and extracted data. We calculated risk ratios (RR) with 95% confidence intervals (CI) for dichotomous data, and used the random-effects model in meta-analyses if there was significant heterogeneity. We assessed the overall quality of the evidence using the GRADE approach. We included 15 trials (two cluster-RCTs) of 4377 adult and child participants. Most trials excluded people with G6PD deficiency. Trials compared various regimens of primaquine with the standard primaquine regimen, or with placebo or no treatment. All trials treated blood stage infection with chloroquine. Alternative primaquine regimens compared to 14-day primaquineRelapse rates were higher over six months with the five-day primaquine regimen than the standard 14-day regimen (RR 10.05, 95% CI 2.82 to 35.86; two trials, 186 participants, moderate quality evidence). Similarly, relapse over six months was higher with three days of primaquine than the standard 14-day regimen (RR 3.18, 95% CI 2.1 to 4.81; two trials, 262 participants, moderate quality evidence; six months follow-up); and with primaquine for seven days followed up over two months, compared to 14-day primaquine (RR 2.24, 95% CI 1.24 to 4.03; one trial, 126 participants, low quality evidence).Relapse with once-weekly supervised primaquine for eight weeks was little different over nine months follow-up compared to 14-day self-administered primaquine in one small study (RR 2.97, 95% CI 0.34 to 25.87; one trial, 129 participants, very low quality evidence). Primaquine regimens compared to no primaquineThe number of people that relapsed was similar between people given five days of primaquine or given placebo or no primaquine (four trials, 2213 participants, high quality evidence; follow-up six to 15 months); but lower with 14 days of primaquine (RR 0.6; 95% CI 0.48 to 0.75; ten trials, 1740 participants, high quality evidence; follow-up seven weeks to 15 months).No serious adverse events were reported. Treatment-limiting adverse events were rare and non-serious adverse events were mild and transient. Trial authors reported that people tolerated the drugs.We did not find trials comparing higher dose primaquine regimens (0.5 mg/kg/day or more) for five days or more with the 14-day regimen. The analysis confirms the current World Health Organization recommendation for 14-day primaquine (15 mg/day) to prevent relapse of vivax malaria. Shorter primaquine regimens at the same daily dose are associated with higher relapse rates. The comparative effects with weekly primaquine are promising, but require further trials to establish equivalence or non-inferiority compared to the 14-day regimen in high malaria transmission settings.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055172732

Download citation: RISBibTeXText

PMID: 24163057

DOI: 10.1002/14651858.cd004389.pub3


Related references

Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2007(1): Cd004389, 2007

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2015(4): Cd010458, 2015

Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical Infectious Diseases 67(10): 1543-1549, 2018

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clinical Infectious Diseases 39(8): 1095-1103, 2004

Relapse of vivax malaria treated with primaquine and report of one case of cyanosis due to primaquine. Amer Jour Med Sci 227(1): 9-12, 1954

Relapse Of Vivax Malaria Treated With Primaquine And Report Of One Case Of Cyanosis (Methemoglobinemia) Due To Primaquine. The American Journal of the Medical Sciences 227(1): 9-12, 1954

In vivo trial for evaluation of chloroquine sensitivity of Plasmodium vivax isolates from Rondonia and efficacy of a new therapeutic schedules of association with primaquine for the treatment of P vivax malaria. Memorias do Instituto Oswaldo Cruz 93(Suppl. 2): 59-60, 1998

Primaquine treatment and relapse in Plasmodium vivax malaria. Pathogens and Global Health 110(1): 1-8, 2016

Therapeutic failure wtih chloroquine and primaquine in malaria by Plasmodium vivax. Enfermedades Infecciosas Y Microbiologia Clinica 16(10): 490-491, 1998

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment. Pharmacogenomics 17(17): 1903-1911, 2016

Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. American Journal of Tropical Medicine and Hygiene 75(4): 605-609, 2006

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 229-241, 2019

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(19): 1875, 2019

High-dose primaquine regimens against relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 78(5): 736-740, 2008

Repeated Plasmodium vivax malaria accesses radical treatment by using chloroquine and primaquine in association. Medecine et Armees 23(1): 3-4, 1995